Your browser is no longer supported. Please, upgrade your browser.
BFRA Biofrontera AG daily Stock Chart
BFRA [NASD]
Biofrontera AG
Index- P/E- EPS (ttm)-0.76 Insider Own- Shs Outstand22.42M Perf Week-10.34%
Market Cap149.80M Forward P/E- EPS next Y-1.38 Insider Trans- Shs Float11.48M Perf Month-16.50%
Income- PEG- EPS next Q-0.34 Inst Own0.09% Short Float0.14% Perf Quarter11.50%
Sales- P/S- EPS this Y-127.80% Inst Trans- Short Ratio0.02 Perf Half Y-41.88%
Book/sh0.68 P/B9.85 EPS next Y-68.30% ROA- Target Price11.00 Perf Year-45.70%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range5.26 - 54.94 Perf YTD-35.13%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-87.84% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low26.89% ATR0.37
Employees154 Current Ratio- Sales Q/Q35.90% Oper. Margin- RSI (14)26.26 Volatility5.51% 4.19%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.08 Prev Close7.13
ShortableYes LT Debt/Eq- EarningsAug 26 AMC Payout- Avg Volume784.51K Price6.68
Recom2.00 SMA20-12.92% SMA50-21.28% SMA200-36.56% Volume59,055 Change-6.31%
May-20-20Upgrade Lake Street Hold → Buy
Apr-20-20Reiterated The Benchmark Company Buy $18 → $8
Nov-20-19Reiterated The Benchmark Company Buy $20 → $18
Oct-11-19Downgrade Lake Street Buy → Hold $17 → $11
Jun-21-18Initiated The Benchmark Company Buy $20
Apr-25-18Initiated Lake Street Buy $19
Oct-14-20 04:30AM  
Oct-09-20 10:32AM  
Oct-08-20 11:04AM  
Sep-22-20 12:02PM  
Sep-11-20 07:33AM  
Sep-09-20 08:00AM  
Aug-27-20 01:00PM  
Aug-26-20 09:51AM  
Aug-20-20 01:00PM  
Aug-19-20 04:30AM  
Aug-18-20 05:00AM  
Aug-13-20 04:50PM  
Aug-10-20 10:00AM  
Jul-27-20 01:15PM  
Jul-23-20 08:30AM  
Jul-14-20 06:08AM  
Jun-30-20 08:30AM  
May-28-20 11:37AM  
May-20-20 02:00PM  
12:00PM  
May-19-20 10:15AM  
May-13-20 04:00AM  
May-12-20 11:00AM  
Apr-21-20 06:00AM  
Apr-20-20 11:07AM  
04:20AM  
Apr-17-20 05:15AM  
Apr-16-20 10:00AM  
Apr-09-20 12:30PM  
Mar-23-20 10:45AM  
Mar-20-20 04:15AM  
Mar-13-20 08:00AM  
Mar-12-20 01:54PM  
Mar-10-20 11:00AM  
Mar-03-20 06:00AM  
Feb-26-20 08:25AM  
Feb-19-20 05:45AM  
Feb-03-20 05:45AM  
Jan-31-20 11:38AM  
Jan-14-20 12:30AM  
Jan-10-20 05:00AM  
Jan-06-20 09:00AM  
Dec-20-19 09:35AM  
Dec-13-19 08:20AM  
Nov-22-19 11:07AM  
Nov-19-19 03:25AM  
Nov-06-19 05:30AM  
Oct-23-19 02:00AM  
Oct-10-19 05:15AM  
Sep-17-19 09:45AM  
05:45AM  
Sep-05-19 11:45AM  
Aug-27-19 02:15AM  
Aug-14-19 05:30AM  
Aug-05-19 09:00AM  
Jul-24-19 06:30AM  
Jul-11-19 05:23AM  
Jun-21-19 03:30AM  
Jun-12-19 10:58AM  
Jun-04-19 10:00AM  
May-29-19 12:00PM  
May-16-19 04:30AM  
Apr-29-19 02:00AM  
Apr-26-19 09:20AM  
Apr-16-19 07:30AM  
05:30AM  
Apr-15-19 06:15AM  
Apr-02-19 08:30AM  
Mar-27-19 09:05AM  
Mar-25-19 11:30AM  
10:00AM  
Mar-20-19 10:50AM  
Mar-19-19 07:42AM  
Feb-25-19 09:30AM  
Feb-11-19 10:02AM  
Jan-22-19 11:18AM  
Jan-08-19 02:02AM  
Dec-27-18 03:31PM  
Nov-26-18 01:08PM  
Nov-21-18 07:35AM  
Nov-16-18 02:20AM  
Nov-05-18 06:26AM  
Oct-15-18 04:19AM  
Oct-10-18 09:22AM  
Oct-01-18 09:08AM  
Sep-26-18 03:15AM  
Sep-24-18 07:44AM  
Sep-19-18 04:03AM  
Sep-17-18 05:17AM  
Jun-12-18 08:00AM  
May-30-18 08:00AM  
May-15-18 07:30AM  
Apr-30-18 08:00AM  
Apr-25-18 12:26PM  
Apr-12-18 10:53AM  
Mar-15-18 10:15AM  
Feb-16-18 04:05PM  
Feb-14-18 10:00AM  
Feb-13-18 07:00PM  
Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma; BF-derm1 for the treatment of chronic and antihistamine-resistant urticaria; and BF-1 for the prophylactic treatment of migraine. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.